STAAR Surgical Company (STAA) |
| 21.13 -0.88 (-4%) 01-13 16:00 |
| Open: | 22.02 |
| High: | 22.11 |
| Low: | 21 |
| Volume: | 1,200,110 |
| Market Cap: | 1,045(M) |
| PE Ratio: | -10.78 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 27.53 |
| Resistance 1: | 24.58 |
| Pivot price: | 22.97 |
| Support 1: | 19.82 |
| Support 2: | 16.49 |
| 52w High: | 30.81 |
| 52w Low: | 13.5 |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| EPS | -1.960 |
| Book Value | 7.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.450 |
| Profit Margin (%) | -41.79 |
| Operating Margin (%) | 25.87 |
| Return on Assets (ttm) | -7.9 |
| Return on Equity (ttm) | -24.6 |
Tue, 13 Jan 2026
What a $22 Million Bet on STAAR Surgical Signals After Third-Quarter Earnings and a 15% Market Lag - AOL.com
Sat, 10 Jan 2026
STAAR Surgical comments on ‘misinformation’ regarding go-shop process - MSN
Fri, 09 Jan 2026
STAAR Surgical Company (STAA) Stock Analysis: Navigating Growth Opportunities with an 18% Potential Upside - DirectorsTalk Interviews
Thu, 08 Jan 2026
Broadwood Partners buys STAAR Surgical (STAA) shares worth $8.8m - Investing.com
Thu, 08 Jan 2026
Yunqi Capital Acquires 750K Shares of STAAR Surgical (STAA) - GuruFocus
Wed, 07 Jan 2026
STAAR Surgical terminates proposed acquisition by Alcon - Modern Retina
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |